21,000 Shares in Neurocrine Biosciences, Inc. $NBIX Bought by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. bought a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 21,000 shares of the company’s stock, valued at approximately $2,948,000.

Several other large investors also recently bought and sold shares of the company. Eastern Bank purchased a new stake in shares of Neurocrine Biosciences in the 3rd quarter worth about $27,000. Geneos Wealth Management Inc. increased its holdings in Neurocrine Biosciences by 143.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares in the last quarter. Quent Capital LLC acquired a new position in Neurocrine Biosciences during the third quarter worth about $32,000. MAI Capital Management lifted its holdings in shares of Neurocrine Biosciences by 101.2% in the second quarter. MAI Capital Management now owns 328 shares of the company’s stock valued at $41,000 after purchasing an additional 165 shares in the last quarter. Finally, True Wealth Design LLC lifted its holdings in shares of Neurocrine Biosciences by 1,215.4% in the second quarter. True Wealth Design LLC now owns 342 shares of the company’s stock valued at $43,000 after purchasing an additional 316 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Buying and Selling at Neurocrine Biosciences

In related news, CEO Kyle Gano sold 36,400 shares of the firm’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $132.70, for a total value of $4,830,280.00. Following the sale, the chief executive officer directly owned 140,407 shares of the company’s stock, valued at approximately $18,632,008.90. This trade represents a 20.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William H. Rastetter sold 18,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $151.82, for a total transaction of $2,732,760.00. Following the transaction, the director directly owned 40,360 shares of the company’s stock, valued at $6,127,455.20. This trade represents a 30.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 80,266 shares of company stock worth $11,400,517. 4.30% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the stock. TD Cowen raised their price objective on shares of Neurocrine Biosciences from $175.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, December 5th. Zacks Research downgraded Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 29th. Weiss Ratings reissued a “hold (c+)” rating on shares of Neurocrine Biosciences in a report on Thursday, January 22nd. JPMorgan Chase & Co. decreased their price objective on Neurocrine Biosciences from $179.00 to $177.00 and set an “overweight” rating on the stock in a research note on Monday, January 12th. Finally, Wall Street Zen upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Sunday, January 18th. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $174.25.

Neurocrine Biosciences Stock Down 0.5%

Shares of NASDAQ:NBIX opened at $133.89 on Wednesday. The company has a market cap of $13.35 billion, a P/E ratio of 32.03, a P/E/G ratio of 0.71 and a beta of 0.28. The business has a fifty day simple moving average of $143.33 and a 200-day simple moving average of $140.24. Neurocrine Biosciences, Inc. has a 52 week low of $84.23 and a 52 week high of $160.18.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Tuesday, October 28th. The company reported $2.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.59. The firm had revenue of $794.90 million for the quarter, compared to analyst estimates of $746.61 million. Neurocrine Biosciences had a return on equity of 15.82% and a net margin of 15.95%.The firm’s quarterly revenue was up 27.8% on a year-over-year basis. During the same period last year, the company earned $1.81 EPS. Sell-side analysts expect that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.